
 Scientific claim: IgA plasma cells that are specific for transglutaminase 2 are scarce in the duodenal mucosa of celiac disease patients when the disease is active. 
 Participant Dynamics: Practitioner vs. Decision-Maker 
 Contextual Arena: The Deliberative Arena (goal: to make a strategic choice) 
 Interaction Trigger: A Point of Confusion (a misunderstanding or contradiction) 
 Dialogue Objective: To Reach a Decision (choose or reject an action) 
```
Practitioner: Good morning, Dr. Ellis. I wanted to discuss the recent study on IgA plasma cells in celiac disease patients. The findings seem counterintuitive to our current treatment approach.

Decision-Maker: Morning, Dr. Patel. Yes, the claim that IgA plasma cells specific for transglutaminase 2 are scarce during active disease is indeed puzzling. How does this contradict what we know?

Practitioner: Well, traditionally, we've assumed these cells would be more prevalent in active celiac disease, given their role in immune response. Yet, this study suggests the opposite. It raises questions about the mechanisms we target with current therapies.

Decision-Maker: Hmm, that’s intriguing. Are you suggesting we reconsider our treatment protocols?

Practitioner: Potentially. If these cells aren’t as abundant during active disease, it might indicate we’re focusing on the wrong targets. Perhaps we should explore alternative pathways that are more active in the disease process.

Decision-Maker: But does the study provide enough evidence to justify such a shift? We need to be cautious about changing strategies based on a single finding.

Practitioner: Absolutely, Dr. Ellis. It’s preliminary, but it could guide further research. I propose we conduct an internal review of our patient cases to see if these findings hold any practical relevance.

Decision-Maker: That sounds reasonable. It’s crucial we validate these observations with our data before making any strategic changes. How soon can we organize this review?

Practitioner: I can coordinate with the research team to start the review process within the next month. We should involve the gastroenterology department to ensure a comprehensive analysis.

Decision-Maker: Agreed. Let’s move forward with that. If the findings are consistent, we’ll need to present our conclusions at the next board meeting. Keep me updated on the progress.

Practitioner: Will do, Dr. Ellis. I’ll ensure a detailed report is prepared. Thank you for your guidance.

Decision-Maker: Thank you, Dr. Patel. Let’s see where this leads us.
```